Palvella Therapeutics (PVLA) said Wednesday that first patients have been dosed in the phase 2 clinical trial of Qtorin 3.9% rapamycin anhydrous gel to treat cutaneous venous malformations.
Venous malformation is the underdevelopment of veins in the body that can lead to abnormal blood vessels.
The company said the study is expected to enroll about 15 patients at least six years old across the US to evaluate the safety and efficacy of Qtorin administered topically once daily.
According to Palvella, the US Food and Drug Administration granted fast track designation to the drug in April 2024.
Price: 14.45, Change: -0.28, Percent Change: -1.90
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。